New Lung Cancer Treatment Company Receives Funding
GLOBE NEWSWIRE - superDimension, Ltd., a privately-owned company that develops minimally invasive interventional pulmonology devices, today announced it has closed on an aggregate $11 million in equity financing. The round was funded by existing investors with the addition of Covidien Ventures.
"We are pleased that our investors have shown such strong commitment to superDimension and our minimally invasive interventional pulmonology technology," said Daniel J. Sullivan, President and Chief Executive Officer. "Since its commercialization, our i * Logic System has experienced strong physician adoption. Electromagnetic navigation bronchoscopy (ENB) has been performed more than 22,000 times and is used in over 350 hospitals worldwide. This additional financing will allow us to further strengthen our commercial infrastructure and sales and marketing team."
ENB is a minimally invasive procedure where a catheter is inserted through the throat and uses Global Positioning System-like technology to biopsy lung lesions and lymph nodes all in one outpatient procedure. ENB provides a three-dimensional virtual roadmap of the lungs that enables a physician to maneuver catheters through multiple branches of the bronchial tree, extending beyond the capabilities of the traditional bronchoscope to distant, previously inaccessible regions of the lungs.
If the targeted lesions are determined to be cancerous, the physician can use ENB to place radiosurgical markers in and around lung tumors to help radiation oncologists treat patients with external beam radiation. The outpatient procedure typically leaves the patient with no more than a sore throat.